<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05118204</url>
  </required_header>
  <id_info>
    <org_study_id>2021-13311</org_study_id>
    <nct_id>NCT05118204</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization</brief_title>
  <acronym>Micro-bupe</acronym>
  <official_title>Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators will test a novel protocol for starting BUP (buprenorphine-naloxone) treatment.&#xD;
      The BUP microdose induction protocol has participants start very low doses of BUP without&#xD;
      stopping other opioids that they are taking. The treatment as usual (TAU) has participants&#xD;
      stop other opioids and experience opioid withdrawal before starting BUP. Investigators&#xD;
      propose to test BUP microdose inductions vs. TAU in a randomized controlled trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will conduct a hybrid type 1 effectiveness-implementation study, using a&#xD;
      pragmatic, open-label, randomized controlled trial (RCT). Investigators will randomize 270&#xD;
      hospitalized patients with (a) chronic pain and (b) opioid misuse or opioid use disorder&#xD;
      (OUD) to a 4-day BUP microdose induction protocol (without stopping full agonists) or 2-day&#xD;
      standard induction (with stopping full agonists), and then link participants to outpatient&#xD;
      BUP treatment when they are released from the hospital. Study assessment visits will occur at&#xD;
      baseline, 1 week, and 1, 3, and 6 months. Assessments will include interviews and urine drug&#xD;
      tests to determine whether participants start BUP, continue BUP, have improvements in pain&#xD;
      and decrease illicit opioid use. During induction and 3-months of follow-up, investigators&#xD;
      will also collect data on mobile devices to assess opioid withdrawal, opioid craving, pain,&#xD;
      and anxiety. These data will allow investigators to assess whether BUP microdosing targets of&#xD;
      engagement-opioid- and pain-related symptoms-mediate OUD outcomes. Exploratory analyses will&#xD;
      also examine pain as a trigger for opioid relapse.&#xD;
&#xD;
      Aim 1: To test the effectiveness of BUP microdose induction (vs. TAU) on OUD outcomes.&#xD;
&#xD;
      H1: The microdose arm (vs. TAU) will have better BUP treatment uptake and retention, and less&#xD;
      illicit opioid use.&#xD;
&#xD;
      H2: Improvements in H1 will be mediated by opioid- and pain-related symptoms.&#xD;
&#xD;
      Aim 2: To test the effectiveness of microdosing (vs. TAU) on pain outcomes. H3: The microdose&#xD;
      arm (vs. TAU) will have less pain intensity and interference, and improved quality of life.&#xD;
&#xD;
      H4: Improvements in H3 will be mediated by OUD outcomes.&#xD;
&#xD;
      Aim 3: To inform future implementation and dissemination efforts, investigators will:&#xD;
&#xD;
      3a) Examine factors influencing reach, adoption, implementation, and maintenance of BUP&#xD;
      microdosing. Investigators will use qualitative and quantitative methods to describe&#xD;
      multi-level factors influencing these domains; 3b) Calculate the cost and examine&#xD;
      cost-effectiveness of BUP microdosing. H5: Compared with TAU, BUP microdosing will be&#xD;
      cost-effective from a societal and a health sector perspective.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2022</start_date>
  <completion_date type="Anticipated">October 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2026</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BUP treatment uptake</measure>
    <time_frame>7 days</time_frame>
    <description>The percentage of participants who start BUP treatment, defined as receiving BUP 7 days after the baseline visit, will be reported for each arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Illicit opioid use</measure>
    <time_frame>1, 3, and 6 months</time_frame>
    <description>The mean number of days of illicit opioid use, defined as self-reported use of heroin, fentanyl, or non-prescribed opioid analgesics in the prior 30 days based on the Addiction Severity Index, will be reported for each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BUP retention in care</measure>
    <time_frame>6 months</time_frame>
    <description>The percentage of participants who are retained in BUP treatment, defined as having a BUP prescription written 180-210 days (6-month retention) after enrollment, will be reported for each arm.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain Intensity</measure>
    <time_frame>3 months</time_frame>
    <description>Mean pain intensity score, measured using the Brief Pain Inventory (BPI), will be reported for each study arm.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pain interference</measure>
    <time_frame>3 months</time_frame>
    <description>Mean pain interference score, measured using the pain interference scale from the BPI, which is a 7-item instrument measuring the impact of pain on daily activities and physical functioning, will be reported for each study arm.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Substance Use Disorders</condition>
  <condition>Opioid-use Disorder</condition>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>BUP microdose induction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive a novel BUP microdose induction protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment As Usual (TAU)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this arm will receive standard BUP induction protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BUP microdose induction</intervention_name>
    <description>Participants will be started on a 4-day BUP microdose induction protocol (without stopping full agonists).&#xD;
Day 1: buprenorphine 0.5 mg every 4 hours Day 2: buprenorphine 1 mg every 4 hours Day 3: buprenorphine 2 mg every 4 hours Day 4: buprenorphine 8 mg every 12 hours</description>
    <arm_group_label>BUP microdose induction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAU</intervention_name>
    <description>2-day standard BUP induction protocol (with stopping full agonists) Day 1: hold all opioids Day 2: buprenorphine 2 mg every 6 hours Day 3: buprenorphine 8 mg every 12 hours</description>
    <arm_group_label>Treatment As Usual (TAU)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Linkage to outpatient BUP treatment</intervention_name>
    <description>Participants will be given an expedited appointment (within 2 weeks) to continue BUP treatment at a Montefiore community health center</description>
    <arm_group_label>BUP microdose induction</arm_group_label>
    <arm_group_label>Treatment As Usual (TAU)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Opioid misuse or OUD&#xD;
&#xD;
          -  Chronic pain&#xD;
&#xD;
          -  Currently taking opioids&#xD;
&#xD;
          -  Fluency in English or Spanish&#xD;
&#xD;
          -  Planned hospitalization for â‰¥ 48 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current OUD treatment (BUP, methadone, naltrexone)&#xD;
&#xD;
          -  Severe alcohol or benzodiazepine use disorder&#xD;
&#xD;
          -  Hypersensitivity to BUP or naloxone&#xD;
&#xD;
          -  Pain due to malignancy&#xD;
&#xD;
          -  Severe untreated mental illness (suicidality, psychosis)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Unable to consent due to pain or cognitive impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Megan Ghiroli</last_name>
    <phone>203-606-8136</phone>
    <email>mghiroli@montefiore.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Megan Ghiroli</last_name>
      <phone>203-606-8136</phone>
      <email>mghiroli@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Aaron Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Aaron D. Fox</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

